Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. · 2010
Read Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. by Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2907344.txt.
Description
Smith and co-authors pooled in 2010 fifty-five randomized trials to pin down how much anthracycline chemotherapy drugs endanger the heart. These drugs are staples against breast and ovarian cancer, lymphoma, myeloma, and sarcoma, but they can damage heart muscle early or years later. Trials of alternative regimens let the team compare clinical heart failure and silent damage rates directly.
Regimens built on anthracyclines carried over five times the odds of clinical heart toxicity of non-anthracycline regimens. One older comparator drug was safer, and drug delivery mattered too: quick bolus dosing roughly quadrupled risk against slow infusion. Two gentler options stood out, the relative epirubicin and fat-wrapped liposomal doxorubicin, each cutting risk steeply. Dose and delivery choices let oncologists trade a measure of punch for heart safety.
Catalog record
| CREATOR | Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |